Symposiums

The oral session consisted of a talk on the 2-year efficacy and safety of guselkumab in the treatment of moderate-to-severe psoriasis from the Phase III VOYAGE 1 trial.

Prof Costanzo welcomed attendees to the symposium and outlined the agenda before explaining the autoimmune pathophysiology that underlies psoriasis.

Prof Fernando Perez-Ruiz opened the symposium, which focussed on the current unmet need in controlling gout and associated comorbidities with current…

This symposium is focused on topical therapies in the treatment of psoriasis and the unmet clinical and patient quality of life needs.

Dermatologists today have more tools than ever at their disposal for managing psoriasis, including newer-generation biologics, which target molecular…

Advances in understanding diabetes pathophysiology and treatment permit individualised therapy based on patient-centred treatment plans.

Fixed-ratio combinations, the co-administration of two injectable therapies in a formulation that can be adjusted through titration, are changing the…

Advances in treatment offerings are moving beyond classical considerations around glucose control to focus on other aspects of the disease.